Cochrane · systematic review · CD012244
Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults
Lu, L, Zeng, J, Wen, Z, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 75%Low 2 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
TACE followed by 3‐DCRT compared to TACE for primary hepatocellular carcinoma
Population: primary hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality: at 3 years TACE followed by 3‐DCRT vs TACE | RR 0.8 [0.73, 0.88] | 7 studies · 552 participants | Low Downgraded: risk of bias |
Proportion of participants without tumour response (CR+PR) TACE followed by 3‐DCRT vs TACE | RR 0.49 [0.39, 0.61] | 8 studies · 632 participants | Low Downgraded: risk of bias |
Serious adverse events TACE followed by 3‐DCRT vs TACE | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life TACE followed by 3‐DCRT vs TACE | no estimate extracted | 1 study · 66 participants | Very low Downgraded: risk of bias, imprecision |
Non‐serious adverse events: leukopenia TACE followed by 3‐DCRT vs TACE | RR 1.12 [0.92, 1.34] | 5 studies · 438 participants | Very low Downgraded: risk of bias, inconsistency |
Non‐serious adverse events: serum transaminases elevation TACE followed by 3‐DCRT vs TACE | RR 1.67 [0.66, 4.27] | 4 studies · 280 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Non‐serious adverse events: total bilirubin elevation TACE followed by 3‐DCRT vs TACE | RR 2.69 [1.34, 5.4] | 2 studies · 172 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants without serum AFP normalisation TACE followed by 3‐DCRT vs TACE | no estimate extracted | 1 study · 96 participants | Very low Downgraded: risk of bias, imprecision |